-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Drug Basics Drug Name: Alishatan ammonia chloride tablets Application matters: Domestic production of pharmaceutical registration acceptance number: CXHL 2000533 country registration classification: chemical drugs 2.3 category acceptance note: in accordance with the provisions of Article 32 of the Administrative Licensing Law of the People's Republic of China, after examination, decided to accept.
not receive a negative or challenged opinion from the Drug Review Center within 60 days from the date of acceptance, the applicant may conduct clinical trials in accordance with the submitted plan.
arshatan ammonia chloride tablets (project code: SAL0107) are ARB/CCB-type compound preparations, and adaptive disorders are tentatively defined as antihypertensive.
The product will be listed, will be listed with the company's Class 1.1 anti-blood pressure drug Xinlitan (Alishatan tablets) to form a strategic synergy to expand the scope of application of Reliantan, further extend the product life cycle of Reliantan, enrich the company's cardiovascular field of innovative product pipeline.
source: Xinlitai Enterprise Announcement.